Nasal Spray With Cell-Penetrating Peptide Delivers GLP-1 Drugs Without Injection
A hyaluronic acid carrier modified with octaarginine cell-penetrating peptide enables nasal delivery of protein drugs regardless of their chemical properties, achieving 20% bioavailability for GLP-1 analogs.
Quick Facts
What This Study Found
Hyaluronic acid modified with octaarginine enables nasal absorption of protein drugs with ~20% bioavailability, independent of the drug's chemical properties, matching the SNAC enhancer used in oral semaglutide.
Key Numbers
~20% BA exenatide; 5x ↑ somatropin; equivalent to SNAC for small peptides; charge-independent; 4 drugs tested (1-22 kDa)
How They Did This
Mouse nasal absorption studies comparing HA-octaarginine carrier with SNAC and unformulated protein drugs, measuring bioavailability relative to subcutaneous injection.
Why This Research Matters
Most peptide drugs require injection. A nasal delivery system achieving 20% bioavailability could transform patient experience for GLP-1 and other peptide medications.
The Bigger Picture
This technology could enable needle-free delivery of multiple peptide therapeutics, improving patient compliance for chronic conditions like diabetes and obesity.
What This Study Doesn't Tell Us
Mouse study — nasal anatomy and absorption differ from humans. Long-term nasal safety not assessed. Regulatory pathway unclear.
Questions This Raises
- ?Does this system achieve similar bioavailability in humans?
- ?Could it deliver larger proteins like insulin or monoclonal antibodies?
- ?What are the long-term effects of repeated nasal exposure to cell-penetrating peptides?
Trust & Context
- Key Stat:
- 20% bioavailability Nasal delivery of exendin-4 using HA-octaarginine carrier, comparable to oral semaglutide's SNAC enhancer
- Evidence Grade:
- Animal study with strong pharmacokinetic data. Promising but requires human validation.
- Study Age:
- Published in 2020. Alternative delivery routes for GLP-1 drugs continue to be developed.
- Original Title:
- Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
- Published In:
- European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 154, 186-194 (2020)
- Authors:
- Tomono, Takumi, Yagi, Haruya, Ukawa, Masami, Ishizaki, Seiya, Miwa, Takahiro, Nonomura, Mao, Igi, Ryoji, Kumagai, Hironori, Miyata, Kohei, Tobita, Etsuo, Kobayashi, Hideo, Sakuma, Shinji
- Database ID:
- RPEP-05168
Evidence Hierarchy
Frequently Asked Questions
Why deliver GLP-1 drugs through the nose?
GLP-1 drugs like exendin-4 and semaglutide currently require injection, which many patients dislike. The nose has thin, blood-vessel-rich tissue that can absorb drugs quickly, and this system achieves 20% bioavailability — good for a non-injection route.
What makes this nasal delivery system work?
The system uses hyaluronic acid (which sticks to nasal tissue) modified with octaarginine, a cell-penetrating peptide that helps drugs cross cell membranes. This combination keeps the drug in contact with nasal tissue and enhances absorption regardless of the drug's properties.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05168APA
Tomono, Takumi; Yagi, Haruya; Ukawa, Masami; Ishizaki, Seiya; Miwa, Takahiro; Nonomura, Mao; Igi, Ryoji; Kumagai, Hironori; Miyata, Kohei; Tobita, Etsuo; Kobayashi, Hideo; Sakuma, Shinji. (2020). Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 154, 186-194. https://doi.org/10.1016/j.ejpb.2020.07.003
MLA
Tomono, Takumi, et al. "Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2020. https://doi.org/10.1016/j.ejpb.2020.07.003
RethinkPeptides
RethinkPeptides Research Database. "Nasal absorption enhancement of protein drugs independent to..." RPEP-05168. Retrieved from https://rethinkpeptides.com/research/tomono-2020-nasal-absorption-enhancement-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.